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Introduction
Pneumococcal disease represents a major cause of morbidity 
and mortality worldwide, and it is usually recognized as 
either invasive (invasive pneumococcal disease (IPD)) or 
non-invasive.1 IPD is a serious condition characterized by 
either the presence of bacteremia or an involvement of major 
organs, in which Streptococcus pneumoniae is isolated from 
normally sterile biofluids, and occurs in up to 25% of cases 
of pneumococcal disease with a fatality rate of at least 10%.2 
Non-IPD is mainly represented by community-acquired 
pneumonia (CAP), which is also associated with a signifi-
cant mortality, especially in the elderly and in patients with 
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Abstract
Background: Pneumonia remain an important public health problem. The primary objective was to determine the proportion 
of community-acquired pneumonia that is attributable to Streptococcus pneumoniae infection; secondary objectives were the 
description of community-acquired pneumonia attributable to Streptococcus pneumoniae according to socio-demographic and 
clinical variables, the clinical evolution of community-acquired pneumonia and the description of the serotype distribution of 
vaccine-preventable disease and antibiotic resistance rate of pneumococcal infections.
Methods: An observational, prospective study was conducted on consecutive patients coming from the community, who 
were hospitalized with pneumonia. Data on admission, at discharge and 30 days after discharge were collected. Logistic 
regression models were used to evaluate the risk factors independently associated with pneumococcal pneumonia.
Results: Among the 193 patients enrolled in the study, the etiology of community-acquired pneumonia was identified in 60 
patients (33%) and 35 (18%) of evaluable patients had community-acquired pneumonia due to Streptococcus pneumoniae. Of 
all clinical characteristics, if no previous antibiotic treatment was performed, there was a 13-fold higher risk of presenting 
community-acquired pneumonia due to Streptococcus pneumoniae (odds ratio, 12.9; 95% confidence interval, 1.42–117.9). 
Moreover, the most frequent isolated serotypes were 35F, 3 and 24 (29%, 23% and 16%, respectively).
Conclusion: The most frequent serotypes in pneumococcal community-acquired pneumonia are 35F, 3, 24, 6 and 7A, 
and thus almost 50% of Streptococcus pneumoniae strains could be covered by pneumococcal conjugate vaccine 13 in adult 
patients with risk factors for pneumococcal infections.
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chronic respiratory diseases and immunosuppression.1,3 As 
new therapies aimed at improving outcomes in CAP patients 
have not been developed over the past two decades, vaccina-
tion has become more and more important in preventing 
pneumococcal disease.1,2,4 Nevertheless, the overall burden 
of respiratory diseases due to S. pneumoniae, the beneficial 
of herd immunity from pediatric vaccinations and the poten-
tial effect of the new recommended vaccination programs for 
adults are difficult to evaluate. This is mainly due to a lack of 
data regarding vaccination coverage in adult patients, diffi-
culties in identifying the etiology of respiratory infections 
and, therefore, the scarcity of data regarding distribution of 
pneumococcal serotypes.5–7 Most of the available studies on 
pneumococcal disease are on IPD, while studies on non-IPD 
are mainly randomized controlled trials (RCTs) or meta-
analysis.2,8,9,10 Although some observational, real-life studies 
on pneumococcal pneumonia were conducted in both the 
United States and Europe, data on non-IPD in Italy are miss-
ing.5–7 Specifically, both type and rate of pneumococcal vac-
cination in adult patients with CAP as well as the type 
pneumococcal serotypes involved in this disease have not 
been evaluated yet in Italy.
Methods
In order to collect real-life data on vaccination coverage and 
serotype identification in CAP, we conducted a prospective, 
observational, cohort study including CAP patients admitted 
at the Respiratory Ward of the IRCCS Policlinico Hospital, 
Milan, Italy, from October 2011 to October 2012.
The primary outcome considered for the sample size cal-
culation is the proportion of patients positive to S. pneumo-
niae diagnosed by blood culture at baseline visit. Published 
data vary noticeably among different studies. A prospective 
study on 184 Sweden patients with CAP admitted to the 
Department of Infectious Disease reported 14.7% of patients 
positive to blood culture.9 Assuming 5% of non-evaluable 
patients, when the sample size is 350 (corresponding to 333 
evaluable patients), a two-sided 95% confidence interval 
using the large sample normal approximation will extend 
3.8% from the observed proportion of patients for an 
expected proportion of 14.7%.11
Ethics approval of study protocol, protocol amendments, 
informed consent forms and other relevant documents was 
obtained prior to study initiation from the Independent Ethic 
Committee (IEC). Informed consent was obtained by each 
patient prior to enrollment in the study.
Blood samples, urinary antigens, sputum and/or naso-
pharyngeal swab, tracheal aspirate and pleural fluid (when 
available) were collected on admission. All samples were 
analyzed for pathogen identification at the Policlinico 
Hospital (local laboratory) and for polymerase chain reac-
tion (PCR) testing, antibiotic resistance patterns and sero-
typing of S. pneumoniae samples at Florence (central 
laboratory).
All statistical analyses were run using SPSS 20 (IBM). 
Categorical data are presented as absolute number (n) and 
percentage (%). Normally distributed data are shown as 
mean with standard deviation (SD), whereas non-normally 
distributed data are presented as median with interquartile 
range (IQR).
Results
A total of 193 patients (age: 78 (66–84) years, 113 male, 
58%) were enrolled. The majority of them had moderate-to-
severe pneumonia: 63% were included in the Pneumonia 
Severity Index risk-class IV-V, while 20% met severe sepsis 
criteria.12,13 Among the entire study population, 26% received 
influenza vaccination during the previous year while 6% 
received the 23-valent polysaccharide vaccine (PPV23). A 
total of 158 patients should have been received pneumococ-
cal vaccine according to national guidelines, but among 
them only 9 patients were previously vaccinated (1). The eti-
ology of CAP was identified in 60 patients (33%) and among 
them 35 (18%) had S. pneumoniae: 2% of samples showed 
resistance to a beta-lactam and 6% to quinolone. In all, 26 
patients had at least one S. pneumoniae sample with a typa-
ble serotype. The majority of patients with pneumococcal 
CAP were treated with a combination therapy with ceftriax-
one and azithromycin (40%), followed by association of 
piperacillin/tazobactam and levofloxacin (29%), levofloxa-
cin monotherapy (17%), association of ceftriaxone and levo-
floxacin, or piperacillin/tazobactam and azithromycin (both 
3%), and monotherapy with piperacillin/tazobactam or 
clarithromycin (both 3%). Concerning hospital resources 
utilization, three patients (9%) with pneumococcal CAP 
required ventilatory support either on admission or during 
hospitalization, the median (IQR) length of stay was 8 (7–
14) days and two (6%) patients were re-hospitalized during 
30 days after discharge. Finally, 14 (7%) patients died during 
hospitalization and 4 (2%) patients during the 30 days after 
discharge.
This study shows that the most frequent serotypes identi-
fied in hospitalized patients with CAP in our center were 35F 
(29%), 3 (23%), 24 (16%), 6 and 7A (10%). Furthermore, we 
showed that among hospitalized patients with CAP, only the 
6% of those meeting the criteria for pneumococcal vaccina-
tion were actually vaccinated. Finally, we found that the 
pneumococcal strains identified in our population were not 
resistant to macrolides and had low resistance rate to both 
beta-lactam (2%) and quinolones (6%).
Discussion
The pneumococcal serotypes identified in our study are sub-
stantially consistent with previous literature, except for the 
interesting finding of a high prevalence of serotype 35F 
(29%).5–7 Few recent experiences showed an increase of 
serotype 35F among children carriers, especially after the 
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extensive use of pneumococcal conjugate vaccine (PCV7) 
and adult patients with both IPD and non-IPD, even if it was 
more likely to be associated with colonization than dis-
ease.14,15 According to our results, we might speculate that 
PCV13 could potentially be protective in about 50% of 
available serotype cases in CAP patients, a finding partly 
consistent with previous studies showing a potential cover-
age from PCV13 between 34% and 80% of cases.5–7 
Moreover, our interesting finding of a lower rate of antibiotic 
resistances of S. pneumoniae, and particularly macrolide 
resistance, is slightly different from previous studies.16,17 
This result could potentially affect the choice of antibiotic 
therapy for S. pneumoniae, at least in our geographical area.
A major limitation of our study consists in its monocenter 
design and in the enrollment of less patients respectful to the 
calculated sample size, with a reduction of the generalizabil-
ity of our results. However, this is the first prospective and 
real-life experience in Italy designed according to a high 
level of microbiological investigations aimed at identifying 
the proportion of CAP that is attributable to S. pneumoniae 
and at describing serotypes distribution and antibiotic resist-
ance patterns of pneumococcal isolates.
Conclusion
In conclusion, our study found that the most frequent sero-
types in pneumococcal CAP are 35F, 3, 24, 6 and 7A and that 
almost 50% of S. pneumoniae strains could be covered by 
PCV 13 in adult patients with risk factors for pneumococcal 
infections.
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